Cargando…

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

PURPOSE: This study investigated the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory mCRC with KRAS G13D mutation. PATIENTS AND METHODS: An assessment of the efficacy and safety of cetuximab-based treatment was performed in an observation-enriched...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Masato, Aoyama, Toru, Ishibashi, Keiichiro, Tsuji, Akihito, Takinishi, Yasutaka, Shindo, Yoshiaki, Sakamoto, Junichi, Oba, Koji, Mishima, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225170/ https://www.ncbi.nlm.nih.gov/pubmed/27878354 http://dx.doi.org/10.1007/s00280-016-3203-7

Ejemplares similares

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report
por: Qiang, Weiguang, et al.
Publicado: (2019)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
por: Segelov, Eva, et al.
Publicado: (2016)

SAT219 Severe Isolated Hypocalcemia With Cetuximab & Irinotecan Chemotherapy
por: Thomas, Melbin, et al.
Publicado: (2023)

Structural dataset for the fast-exchanging KRAS G13D
por: Lu, Jia, et al.
Publicado: (2015)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Clinical significance of the KRAS G13D mutation in anastomotic recurrence of colorectal cancer
por: Matsunaga, Keigo, et al.
Publicado: (2023)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types †
por: Attoye, Bukola, et al.
Publicado: (2021)

Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma
por: De Falco, Elena, et al.
Publicado: (2021)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

Reduced dynamic complexity allows structure elucidation of an excited state of KRAS(G13D)
por: Chao, Fa-An, et al.
Publicado: (2023)

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
por: Liu, Yanfei, et al.
Publicado: (2022)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
por: Burtness, Barbara, et al.
Publicado: (2016)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
por: Chen, Dawei, et al.
Publicado: (2015)

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation
por: Charitou, Theodosia, et al.
Publicado: (2019)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
por: Spindler, Karen-Lise G, et al.
Publicado: (2011)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations
por: Gollins, Simon, et al.
Publicado: (2017)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
por: Barmettler, Hanna, et al.
Publicado: (2012)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Cetuximab–siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib
por: Sreedurgalakshmi, K., et al.
Publicado: (2021)

Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports
por: Okada, Satoshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b37b0m9nt3jb6cftjlpaimgfuu